Notably, on July 28, 2022, ImmunityBio reported that the FDA has accepted a biologics license application (BLA) for the IL-15 agonist N-803 (AnktivaTM) for the treatment of non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ patients who had not responded to bacillus Calmette-Guerin (BCG) (13–15). This evidence concerns the gene IL15 and cancer.